Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 2
1957 1
2002 1
2009 2
2010 2
2011 2
2012 1
2014 1
2015 3
2018 2
2019 4
2020 3
2021 10
2022 11
2023 8
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
COPD-bronchiectasis overlap syndrome.
Hurst JR, Elborn JS, De Soyza A; BRONCH-UK Consortium. Hurst JR, et al. Eur Respir J. 2015 Feb;45(2):310-3. doi: 10.1183/09031936.00170014. Eur Respir J. 2015. PMID: 25653262 Free article. No abstract available.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Among authors: duckers j. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
Gaining an Understanding of Pneumocystosis in Wales.
Ayling-Smith J, Backx M, Grant E, Dhillon R, Duckers J, Hood K, White PL. Ayling-Smith J, et al. Among authors: duckers j. J Fungi (Basel). 2023 Jun 13;9(6):660. doi: 10.3390/jof9060660. J Fungi (Basel). 2023. PMID: 37367596 Free PMC article.
Perceptions of inspiratory muscle training in adults recovering from COVID-19.
Shelley J, Hudson J, Mackintosh KA, Saynor ZL, Duckers J, Lewis K, Davies GA, Berg RMG, McNarry MA. Shelley J, et al. Among authors: duckers j. PLoS One. 2022 Nov 3;17(11):e0270620. doi: 10.1371/journal.pone.0270620. eCollection 2022. PLoS One. 2022. PMID: 36327314 Free PMC article.
Systemic comorbidities in bronchiectasis.
Gale NS, Bolton CE, Duckers JM, Enright S, Cockcroft JR, Shale DJ. Gale NS, et al. Among authors: duckers jm. Chron Respir Dis. 2012;9(4):231-8. doi: 10.1177/1479972312459973. Chron Respir Dis. 2012. PMID: 23129800 Free article.
49 results